RxDoctor Payments Data

Deepti Sinha

Sleep Medicine · Burlingame, CANPI 1124213178

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 51.1% of the total. Reporting peaked in 2019 at $113 and has fallen 56.6% since, to $49 in 2025. That places this record below the midpoint for sleep medicine clinicians in CA, where the typical reported total is $1,477.

$348in general payments, 2019–2025

Across 15 payments — averaging $23.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$178
  • Lilly USA, LLC$49
  • Resmed Corp$40
  • Inspire Medical Systems, Inc.$26
  • Eisai Inc.$23
  • Merck$18
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$348100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$348 in reported general payments places this provider in the 25th percentile of 200 sleep medicine providers in California.

See all sleep medicine providers in California →

Medicare billing

Part B allowed, 2024
$66,901
Medicare patients
162
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tasimelteon13$227,739
DayvigoLemborexant24$7,887
Azelastine Hcl15$432
Zolpidem Tartrate ErZolpidem Tartrate14$373
Zolpidem Tartrate55$338
Clonazepam25$330
Gabapentin20$258
Zaleplon14$96
Lorazepam21$50
Quetiapine Fumarate14$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Dayvigo$23$7,88724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 200 sleep medicine providers in California.

Other sleep medicine in Burlingame

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →